Your session is about to expire
← Back to Search
Sleep Apnea's Cardiovascular Impact on Women With Obesity
Phase < 1
Recruiting
Research Sponsored by University of Missouri-Columbia
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Obese (BMI ≥30 kg/m2)
18-45 years of age (premenopausal)
Must not have
Diagnosed sleep apnea or Oxygen desaturation index >10 events/hr
Pregnancy, breastfeeding, oral hormonal contraceptive use
Timeline
Screening 3 weeks
Treatment Varies
Follow Up continuous measurement of vascular conductance during infusion of each drug (final 3 min of normoxia and hypoxia).
Awards & highlights
No Placebo-Only Group
Summary
This trial looks at how sleep apnea affects cardiovascular disease in women, who may be at greater risk than men.
Who is the study for?
This trial is for premenopausal women aged 18-45, who are either obese (BMI ≥30) or of healthy weight (BMI between 18 and ≤25). Participants should not have sleep apnea, cardiovascular issues, clotting disorders, high blood pressure, diabetes, PCOS, communication barriers or be using certain medications including oral contraceptives.
What is being tested?
The study investigates how low oxygen levels affect the cardiovascular system differently in men and women and if obesity influences this. It involves drugs like Phentolamine and Norepinephrine to study blood vessel responses under hypoxic conditions.
What are the potential side effects?
Potential side effects may include changes in blood pressure or heart rate due to the drugs used to manipulate vascular responses. Hypoxia exposure might cause shortness of breath or lightheadedness.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowSelect...
My BMI is 30 or higher.
Select...
I am between 18 and 45 years old and have not gone through menopause.
Select...
My BMI is between 18 and 25.
Exclusion Criteria
You may be eligible for the trial if you check “No” for criteria below:Select...
I have sleep apnea or my oxygen levels drop frequently at night.
Select...
I am not pregnant, breastfeeding, or using oral hormonal contraceptives.
Select...
I have a nerve or neurological condition.
Select...
I am allergic to lidocaine.
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ continuous measurement of vascular conductance during infusion of each drug (final 3 min of normoxia and hypoxia).
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~continuous measurement of vascular conductance during infusion of each drug (final 3 min of normoxia and hypoxia).
Treatment Details
Study Objectives
Study objectives can provide a clearer picture of what you can expect from a treatment.Primary study objectives
Change in forearm vascular conductance with intra-arterial drug infusion
Awards & Highlights
No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.
Trial Design
1Treatment groups
Experimental Treatment
Group I: Hypoxia ExposureExperimental Treatment5 Interventions
A physician will place a catheter in the brachial artery for intra-arterial pharmacological infusions. The following drugs will be administered to each participant under room air (normoxic) and low oxygen (hypoxic) conditions: phenylephrine, dexmedetomidine, norepinephrine, phentolamine (see Interventions for details).
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Norepinephrine
2014
Completed Phase 4
~1780
Phenylephrine
2014
Completed Phase 4
~2040
Dexmedetomidine
2015
Completed Phase 4
~2050
Find a Location
Who is running the clinical trial?
University of Missouri-ColumbiaLead Sponsor
377 Previous Clinical Trials
628,585 Total Patients Enrolled
22 Trials studying Obesity
2,134 Patients Enrolled for Obesity
Media Library
Eligibility Criteria:
This trial includes the following eligibility criteria:- I have sleep apnea or my oxygen levels drop frequently at night.My BMI is 30 or higher.I am between 18 and 45 years old and have not gone through menopause.You are currently smoking or using nicotine products.I am not pregnant, breastfeeding, or using oral hormonal contraceptives.I have a nerve or neurological condition.My BMI is between 18 and 25.I have no major heart, liver, kidney, or lung diseases.You have difficulty communicating with the medical team due to language or hearing difficulties.I have a condition or take medication that affects my blood's ability to clot.I have diabetes or polycystic ovarian syndrome.I am allergic to lidocaine.
Research Study Groups:
This trial has the following groups:- Group 1: Hypoxia Exposure
Awards:
This trial has 1 awards, including:- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
Timeline:
This trial has the following timeline:- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Obesity Patient Testimony for trial: Trial Name: NCT04436731 — Phase < 1
Share this study with friends
Copy Link
Messenger